Opportunistic coinfection with Pneumocystis jirovecii and Coccidioides immitis associated with idelalisib treatment in a patient with chronic lymphocytic leukaemia
- 29 April 2020
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 13 (4) , e234113
Abstract
We describe a case of opportunistic coinfections with Coccidioides immitis and Pneumocystis jirovecii following treatment with idelalisib, a phosphoinositide 3-kinase inhibitor, for chronic lymphocytic leukaemia. This is the first case of pulmonary coccidioidomycosis reported in association with idelalisib. We review challenges related to diagnosis of opportunistic infections in this context. This report illustrates (1) the uncommon occurrence of two opportunistic infections concurrently or in rapid succession, (2) the importance of maintaining a broad differential diagnosis in the setting of an atypical imaging finding, slow clinical response or when immunomodulatory drugs are used, and (3) the challenges associated with non-invasive serological testing in individuals with haematological malignancy on immunomodulatory therapy.Keywords
This publication has 8 references indexed in Scilit:
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approachHaematologica, 2017
- A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical TrialsBlood, 2016
- Coccidioides parenchymal cerebral abscess in the setting of lymphomaJournal of Clinical Neuroscience, 2015
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2014
- A Multicenter Evaluation of Tests for Diagnosis of HistoplasmosisClinical Infectious Diseases, 2011
- CoccidioidomycosisClinical Infectious Diseases, 2005
- Coccidioidomycosis in Patients With Hematologic MalignanciesArchives of internal medicine (1960), 2005
- Historical Perspective on InfectionProtist, 2002